Immucor Inc. (NSDQ:BLUD) tapped the former CEO of Medtronic Inc. (NYSE:MDT) to be its new CEO, succeeding Joshua Levine as of Oct. 17.
Immucor, which was the target of a $1.97 billion takeover by TPG Capital affiliate IVD Holdings Inc. in July, said Hawkins will also serve as an advisor to TPG "on its ongoing efforts to identify investment opportunities in the healthcare industry," according to a press release. Levine is stepping down for personal reasons, he said.
It’s been a busy week for Hawkins, who was named yesterday as an “entrepreneur in residence” by the FDA.
"I am very excited for the opportunity to be taking over as CEO of Immucor, a market leader in helping secure the world’s blood supply through automation. Immucor’s talented management has brought forth innovation that is improving the practice of transfusion medicine," he said in prepared remarks.
"I am grateful for the opportunity I have had to lead the talented team at Immucor. Unfortunately, the challenges of having my family in California and my office in Atlanta ultimately became unsustainable, which led to my decision to step down," Levine added.
Hawkins stepped down as CEO of Medtronic, the world’s largest pure-play medical device maker, in April.
Immucor shareholders received $27.00 in cash for each share of stock, about 30 percent higher than the stock’s trading price prior to the announcement July 5.The Norcross, Ga.-based company manufactures and sells systems for detection and identification of blood properties prior to transfusion.